DHG`s largest shareholder is State Capital Investment Corporation (SCIC) with 56.6 million shares or 43.31% of the medicine maker`s charter capital.
Japan-based Taisho Pharmaceutical completed the purchase of 9.2 million shares at DHG Pharmaceutical (DHG), increasing its stake at the latter to 32% or 41.8 million shares, Taisho said in a filing to the Ho Chi Minh City Stock Exchange (HoSE).
Before the deal, the Japanese group owned over 32.6 million shares of the Vietnamese firm or a 24.94% stake.
With a public offer of VND120,000 (US$5.20) apiece, Taisho Pharmaceutical was calculated to have spent over VND1.1 trillion (US$47.25 million) to increase its holding in DHG.
Taisho Pharmaceutical in early June spent VND85.5 billion (US$3.71 million) for 650,000 shares of DHG, raising its holding in the Vietnamese medicine producer to 24.94%.
DHG's largest shareholder is State Capital Investment Corporation (SCIC) with 56.6 million shares or a 43.31% stake.
On July 4, DHG Pharmaceutical's foreign ownership limit was removed, as a result, the company adjusted its targets of revenue and pre-tax profit growth of at least 13% and 7%, respectively.
At the close on August 20, DHG's share value declined for a fifth straight day, touching to VND96,000 (US$4.13) per share. The stock stayed still on August 21.
Taisho Pharmaceuticals, headquartered in Tokyo, is a leading Japanese pharmaceutical company specializing in the manufacturing of pharmaceutical products and non-prescription dietary supplements under well-known brands.
Illustrative photo.
|
With a public offer of VND120,000 (US$5.20) apiece, Taisho Pharmaceutical was calculated to have spent over VND1.1 trillion (US$47.25 million) to increase its holding in DHG.
Taisho Pharmaceutical in early June spent VND85.5 billion (US$3.71 million) for 650,000 shares of DHG, raising its holding in the Vietnamese medicine producer to 24.94%.
DHG's largest shareholder is State Capital Investment Corporation (SCIC) with 56.6 million shares or a 43.31% stake.
On July 4, DHG Pharmaceutical's foreign ownership limit was removed, as a result, the company adjusted its targets of revenue and pre-tax profit growth of at least 13% and 7%, respectively.
At the close on August 20, DHG's share value declined for a fifth straight day, touching to VND96,000 (US$4.13) per share. The stock stayed still on August 21.
Taisho Pharmaceuticals, headquartered in Tokyo, is a leading Japanese pharmaceutical company specializing in the manufacturing of pharmaceutical products and non-prescription dietary supplements under well-known brands.
Other News
- Over US$4.6 billion poured into Vietnamese startups in past decade
- Nvidia, FPT invest US$200 million in AI factory
- US-based Rosen Partner to invest in world-class entertainment complex projects in Vietnam
- Foreign capital set to dominate Vietnam’s M&A landscape
- Samsung to invest US$1 billion annually in Vietnam
- Thai bank acquires Vietnamese finance company
- Vietnam appreciates support from int’l friends in nation-building: PM
- Vietnam, Hungary call for stronger economic ties
- Vietnam - Indonesia expand cooperation to include green growth, EV ecosystem
- Vietnam ready to absorb investment capital in semiconductor industry
Trending
-
Vietnamese Gov't to continue VAT cut for second half of 2024
-
Vietnam news in brief - May 4
-
Four- and five-star hotels to boom in Hanoi as tourism rebounds
-
Vietnam seeks more information on Cambodia’s Funan Techo canal project
-
Hanoi strives to ensure smooth high school exams
-
Carnaval Ha Long 2024 woos tourists with fireworks and drone light shows
-
Trivial jobs: Hanoians strive to keep their old trades alive
-
Affordable, quality tours offered at Hanoi Tourism Festival 2024
-
Introduction of community tourism area in Hanoi herb kingdom